Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook

Arcutis Biotherapeutics

05/08/2026 21:08

Overview
US dermatology drug maker's Q2 product revenue rose 59% yr/yr, driven by ZORYVE demand
Company raised 2026 full-year net product sales guidance to $525 mln–$540 mln
FDA approved expanded indication for ZORYVE cream for children with plaque psoriasis

Outlook
Arcutis raises 2026 full-year net product sales guidance to $525 mln–$540 mln
Company expects topline results for Phase 2 vitiligo study in Q4 2026
FDA sets target action date of Feb 23, 2027 for ZORYVE cream 0.05% sNDA

Result Drivers
ZORYVE DEMAND - Co said Q2 revenue growth was primarily driven by increased demand for ZORYVE products
PATIENT ACCESS INITIATIVES - Co launched virtual health platform and partnered with AI-enabled healthcare provider to facilitate access to ZORYVE
SALES FORCE EXPANSION - Co completed hiring of targeted sales team for primary care and pediatric providers to support ZORYVE commercialization

Company press release: ID:nGNX6CXCG9

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
 
$129.86 mln
 
Q2 EPS
 
$0.11
 
Q2 Net Income
 
$15.009 mln
 
Q2 Operating Expenses
 
$113.43 mln
 
Q2 Operating Income
 
$16.43 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Arcutis Biotherapeutics, Inc. is $35.00, about 34.5% above its August 4 closing price of $26.03
The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 47 three months ago

Reuters Recommended Reads
Aug 4 - Acadia Pharmaceuticals Q2 revenue rises on DAYBUE STIX demand, lifts 2026 outlook
Aug 3 - Krystal Biotech Q2 revenue rises on VYJUVEK strength
Aug 4 - Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)